Boosting the Body’s Own Muscle Repair Offers New Hope for Muscular Dystrophy

Muscular dystrophies have long been framed as genetic problems in need of genetic fixes: replace or repair the faulty gene, and the disease should slow. A new review in Cell Regeneration argues that this framing misses a therapeutic opportunity hiding in plain sight. So-ichiro Fukada, Atsushi Kubo, Motoi Kanagawa and Yoshitsugu Aoki survey the case for pro-regenerative drugs, treatments that do not restore the missing Dystrophin protein but instead amplify the body’s intrinsic capacity to rebuild muscle. Their central puzzle is striking: if regenerated fibers still lack Dystrophin and should die again, why do regeneration-boosting therapies produce lasting benefit? The answer, they propose, reshapes how muscular dystrophy might be treated, especially in patients whom current medicines cannot help.

The scale of the delivery problem motivates the whole enterprise. The human body contains more than 600 individual skeletal muscles, and cell transplantation approaches, including those built on induced pluripotent stem (iPS) cell-derived muscle stem cells, remain largely local. Muscle satellite cells, the resident stem cells that drive regeneration, cannot circulate in the bloodstream or cross physiological barriers, which confines iPS-derived satellite cell therapies to injection into accessible sites. Molecular therapies such as exon-skipping antisense oligonucleotides are delivered systemically and raise Dystrophin throughout the body, but they depend on myofibers still being present. In advanced disease, where up to 60 percent of skeletal muscle mass may be lost, the authors argue that regenerative medicine, including pro-regenerative drugs, is the only strategy that can generate new fibers de novo.

The strongest proof of concept comes from histone deacetylase (HDAC) inhibitors. In preclinical models, HDAC inhibitors enhanced muscle regeneration, and one of them, Givinostat, went on to show clinical benefit in the phase III EPIDYS trial and was approved in the United States in 2024. In a phase II trial, the drug increased the cross-sectional area of biceps brachii fibers by 77.7 percent and reduced the fraction of fibrosis by 27.4 percent, necrosis by 43.5 percent and fatty replacement by 37.5 percent in biopsy samples. Those numbers are remarkable for a drug that never touches the Dystrophin gene, and they anchor the review’s guiding question: how can a pro-regenerative drug restore and sustain muscle strength without gene complementation?

The authors’ hypothesis draws on an unexpected observation about timing. Conditional knockout experiments show that when Dystroglycan or Fukutin, components of the Dystrophin-glycoprotein complex, are deleted in myofibers after birth using MCK-Cre mice, the resulting dystrophic phenotype is relatively mild. When the same genes are deleted earlier, in all Myf5-positive cells including developing muscle and most satellite cells, using Myf5-Cre, the phenotype is severe. Growing myofibers appear far more sensitive to the loss of Dystrophin and related proteins than mature adult fibers. Under sedentary conditions, adult fibers whose causative gene has been deleted do not undergo significant necrosis or severe scarring. If that holds for Dystrophin, newly regenerated fibers in a treated patient might survive far longer than their birth dates would suggest, though the authors stress this conclusion warrants rigorous experimental and clinical validation, and that MCK-Cre Fukutin knockout mice remain vulnerable to exercise-induced stress.

Animal models complicate and enrich this picture. The classic mdx mouse on the C57BL/10 background, the longest-serving model of Duchenne muscular dystrophy, is notably resistant: its muscle mass exceeds that of wild-type controls up to at least 52 weeks of age. But mdx mice on a DBA/2 background show more severe regenerative defects and pronounced DMD-like phenotypes, and DBA/2-mdx mice display low regenerative signatures, fewer central myonuclei and revertant fibers, compared with C57BL/10-mdx. That strain difference suggests something important: enhancing regenerative capacity could ameliorate severe dystrophic symptoms even without gene replacement. Models in rats, dogs, pigs and nonhuman primates, which resemble human disease more closely than the standard mdx mouse, will matter for testing next-generation drugs.

What should such drugs target? The review organizes candidates by cell type. Muscle satellite cells are the obvious focus, but simply stimulating their proliferation backfires, because proliferating cells must withdraw from the cell cycle to differentiate. The most instructive targets regulate self-renewal instead. A small molecule called SAT3247, developed after researchers found that asymmetric division-mediated self-renewal is compromised in mdx mice, enhances regeneration in preclinical models and is now in a phase II trial. Transient STAT3 inhibition promotes satellite cell proliferation in mdx mice even though sustained inhibition does the opposite; CEP-701 improves engraftment of transplanted cells without affecting myoblast proliferation in standard culture; Integrin beta-1 activation potentiates growth factor signaling; and a single intramuscular Wnt7a injection expanded satellite cells and increased muscle function in mdx mice. Many of these studies used local administration, and the authors flag systemic delivery as the major unsolved challenge.

Two other cell populations offer complementary leverage. Fibro/adipogenic progenitors play a double game: under physiological conditions they support repair by promoting macrophage infiltration and satellite cell proliferation, but in dystrophic muscle they are a major source of the fat accumulation and fibrosis that mark disease progression. HDAC inhibitors act partly through these cells, inducing Follistatin and thereby promoting myogenic differentiation indirectly. Tyrosine kinase inhibitors such as Imatinib and Nilotinib reduce FAP-mediated fibrosis but may suppress satellite cell proliferation and carry significant side effects, limiting their use. More provocatively, CAR-T cells engineered against fibroblast activation protein on FAPs reduced fibrosis and enhanced gene therapy in DBA/2-mdx mice. On the immune side, depleting the inflammatory receptor TLR4 in mdx mice improved muscle function and histopathology while shifting macrophages from an inflammatory iNOS-positive state toward a resolving CD206-positive state, and regulatory T cells ameliorate disease severity, with interleukin-4-conjugated gold nanoparticles improving muscle function in mice through Treg expansion.

MicroRNAs add another layer. The muscle-specific miR-206 promotes myoblast fusion, yet a decoy that downregulated it by roughly 40 percent improved muscle histology and motor function in mdx mice, while complete loss of the miR-206/133b cluster leaves development and regeneration unaffected, hinting that partial modulation, not ablation, is the therapeutic window. More recently, systemic delivery of antisense oligonucleotides targeting miR-33 ameliorated muscular dystrophy by enhancing regeneration, with inhibition of miR-33a/b increasing expression of genes involved in cell proliferation and inflammation. Suppression of myofiber necrosis remains the other half of the equation: the myosin inhibitor EDG-5506 (Sevasemten) suppressed fibrosis and creatine kinase in mdx mice, and in a phase I trial in adults with Becker muscular dystrophy, serum biomarkers of muscle injury progressively decreased during treatment. Still, the field cannot fully answer why Dystrophin-deficient fibers die at all, and even successful regeneration is useless without proper innervation, since Dystrophin is enriched at neuromuscular junctions and repeated necrosis secondarily damages them.

The review’s most consequential claim concerns who can be treated. Current therapies, gene therapy and exon skipping among them, depend on existing myofibers and primarily benefit younger patients, leaving those with advanced disease unable to benefit. Pro-regenerative drugs could change that calculus, and evidence suggests the window may not close: in one study, modulating immune responses enhanced regenerative capacity even in advanced-stage DMD model mice, though the authors note those animals were subjected to daily micropin injury rather than being a naturally occurring chronic model. Reactivating the remaining satellite cells, the authors conclude, could expand treatment eligibility to a broader patient population and, in combination with AAV-based and exon-skipping therapies, rebuild enough tissue for those approaches to work. Key unknowns persist, including how satellite cells self-renew, which appears to occur stochastically and predominantly between days five and seven after injury, and how the pathological niche that suppresses myogenesis might be converted into a regenerative one. Single-nucleus RNA sequencing of human DMD samples and patient-derived platforms such as urine-derived stem cells are expected to accelerate the search for targets. The promise is real, but so are the caveats, and the authors are careful to distinguish what has been demonstrated in mice and early trials from what remains to be validated in patients.

Subject of Research: Pro-regenerative drug development for muscular dystrophy

Article Title: Systemic regeneration medicines for muscular dystrophy: progress and challenges in pro-regenerative drug development

Article References: Fukada, S.-I., Kubo, A., Kanagawa, M., & Aoki, Y. (2026). Systemic regeneration medicines for muscular dystrophy: progress and challenges in pro-regenerative drug development. Cell Regeneration, 15(1), Article 21. https://doi.org/10.1186/s13619-026-00296-8

Image Credits: AI Generated

DOI: 10.1186/s13619-026-00296-8

Keywords: muscular dystrophy, Duchenne muscular dystrophy, muscle regeneration, satellite cells, HDAC inhibitors, Givinostat, fibro/adipogenic progenitors, regulatory T cells, microRNAs, Dystrophin, cell transplantation, drug development